Home

Moderna, Inc. - Common Stock (MRNA)

28.69
+1.10 (3.99%)
NASDAQ · Last Trade: Jul 2nd, 2:46 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close27.59
Open27.31
Bid28.83
Ask28.85
Day's Range26.81 - 29.85
52 Week Range23.15 - 129.39
Volume14,593,284
Market Cap11.10B
PE Ratio (TTM)-3.286
EPS (TTM)-8.7
Dividend & YieldN/A (N/A)
1 Month Average Volume9,599,722

Chart

About Moderna, Inc. - Common Stock (MRNA)

Moderna Inc is a biotechnology company focused on developing innovative messenger RNA (mRNA) therapeutics and vaccines for a wide array of diseases. Utilizing its proprietary mRNA technology platform, Moderna aims to harness the body's own cellular machinery to produce proteins that can help prevent or treat illnesses, including infectious diseases, cancer, and rare genetic disorders. The company gained significant attention for its development of an effective COVID-19 vaccine, but its pipeline also includes various other candidates in different stages of clinical development aimed at addressing unmet medical needs. Through its research and development efforts, Moderna seeks to transform the field of medicine and improve patient outcomes globally. Read More

News & Press Releases

Tuesday's session: top gainers and losers in the S&P500 indexchartmill.com
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday.
Via Chartmill · July 1, 2025
Got $200? 2 Biotech Stocks to Buy and Hold Foreverfool.com
Via The Motley Fool · July 1, 2025
Did Down-And-Out Moderna Just Unlock The Key To Its Future Profitability?investors.com
Shares have long struggled, but things could be looking up for Moderna stock in the face of new flu shot results.
Via Investor's Business Daily · June 30, 2025
Moderna's mRNA Flu Vaccine Outperforms Standard Shotsbenzinga.com
Moderna's mRNA flu vaccine showed 26.6% better efficacy than a standard flu shot in adults 50 and older during a global Phase 3 study.
Via Benzinga · June 30, 2025
What's going on in today's pre-market session: S&P500 moverschartmill.com
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the S&P500 top gainers and losers in today's pre-market session.
Via Chartmill · June 30, 2025
Moderna Stock Surges Pre-Market As Flu Vaccine Shows Positive Results In Late-Stage Trialstocktwits.com
The data is key to receiving approvals for both the individual vaccine candidate and the company’s seasonal flu-COVID combination vaccine candidate.
Via Stocktwits · June 30, 2025
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older
Via ACCESS Newswire · June 30, 2025
CDC Vaccine Panel Overhauled by RFK Jr. Votes To Drop Mercury Preservative, Critics Sound Alarmstocktwits.com
The panel also voted to recommend Merck’s RSV antibody drug Enflonsia for newborns whose mothers didn’t receive prenatal protection.
Via Stocktwits · June 26, 2025
RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Groupbenzinga.com
Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts.
Via Benzinga · June 26, 2025
Moderna, Pfizer, Novavax Draw Bearish Buzz Ahead Of CDC Panel With Vaccine Skepticsstocktwits.com
RFK Jr.'s newly appointed CDC panel, half of whom oppose vaccines, prepares to review key data on COVID, RSV, and flu shots.
Via Stocktwits · June 25, 2025
Uncover the latest developments among S&P500 stocks in today's session.chartmill.com
Let's have a look at what is happening on the US markets one hour before the close of the markets on Tuesday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · June 24, 2025
1 Volatile Stock with Impressive Fundamentals and 2 to Be Wary Of
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.
Via StockStory · June 20, 2025
AI Meets Oncology: Caris Life Sciences' $5.35B IPO Tests Investor Appetite for Precision Medicinebenzinga.com
Via Benzinga · June 17, 2025
Robert F. Kennedy Jr.'s CDC Overhaul 'Critically Weakened' US Vaccine Program, Say Ousted Expertsbenzinga.com
Fired vaccine experts warn that Health Secretary Robert F. Kennedy Jr.'s overhaul of the CDC's key vaccine advisory panel threatens public health and undermines decades of immunization progress, potentially impacting pharmaceutical companies and healthcare markets.
Via Benzinga · June 17, 2025
Top S&P500 movers in Monday's sessionchartmill.com
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
Via Chartmill · June 16, 2025
Monday's session: top gainers and losers in the S&P500 indexchartmill.com
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · June 16, 2025
Which S&P500 stocks are gapping on Monday?chartmill.com
Wondering what's happening in today's session regarding gap up and gap down stocks? Explore the S&P500 index on Monday to uncover the stocks that are gapping in the S&P500 index.
Via Chartmill · June 16, 2025
FDA Expands Moderna's RSV Vaccine Use To At-Risk Adults Aged 18–59 Amid CDC Panel Shake-Upbenzinga.com
The U.S. Food and Drug Administration expanded approval of Moderna Inc.'s (NASDAQ: MRNA) respiratory syncytial virus vaccine.
Via Benzinga · June 13, 2025
Moderna’s RSV Vaccine Gets FDA Nod For Younger At-Risk Adults: Retail Stays Guarded Amid RFK Jr’s Immunization Shake-Upstocktwits.com
The company plans to make mRESVIA available for both younger and older adults in the U.S. ahead of the 2025-2026 respiratory virus season.
Via Stocktwits · June 13, 2025
3 Healthcare Stocks with Questionable Fundamentals
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 8.4%. This drawdown was discouraging since the S&P 500 held its ground.
Via StockStory · June 13, 2025
Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease
Expanded indication builds on existing U.S. FDA approval of mRESVIA for adults aged 60 and older
Via ACCESS Newswire · June 12, 2025
Exploring the top movers within the S&P500 index during today's session.chartmill.com
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session.
Via Chartmill · June 12, 2025
Is it Time to Dump Your Shares of Moderna?fool.com
Via The Motley Fool · June 12, 2025
RFK Jr. Appoints Vaccine Critics To CDC Vaccine Panel After Firing Entire Advisory Committee: Reportbenzinga.com
Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC's Advisory Committee on Immunization Practices.
Via Benzinga · June 12, 2025
CDC Reinstates 450 Workers After Layoffs Spark Public Health Concerns: Reportbenzinga.com
The U.S. Centers for Disease Control and Prevention reversed course Wednesday, reinstating approximately 450 employees previously laid off under the Trump administration's federal workforce reduction initiative.
Via Benzinga · June 12, 2025